

REMARKS

Upon entry of this response, claims 1-20 are pending. Claim 19-20 have been added. No claims have been amended or canceled. No new matter has been added by way of this response.

Election/Restrictions Required

In the Official Action of April 16, 2007, the Office required an election of one of the following inventions under 35 U.S.C. § 372:

Group I: Claims 1-15, drawn to products and methods of using the compound of formula (I) where **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is substituted phenyl; as depicted in Claim 1, pages 3-5 and Example 1 of the specification.

Group II: Claims 1-15, drawn to products and methods of using the compound of formula (I) wherein **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is substituted pyrrolidine; as depicted in Claim 1, pages 3-5 and Example 3 of the Specification.

Group III: Claims 1-15, drawn to products and methods of using the compound of formula (I) wherein **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is biphenyl; as depicted in Claim 1, pages 3-5 and Example 5 of the Specification.

Group IV: Claims 1-15, drawn to products and methods of using the compound of formula (I) wherein **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is phenyl-morpholine; as depicted in Claim 1, pages 3-5 and Example 8 of the Specification.

Group V: Claims 16-18, drawn to methods of using the compound of formula (I) where in the disorder is arterial restenosis.

In response to the Office's invention restriction requirement, Applicants *provisionally* elect, with traverse, to prosecute the invention of Group I, encompassing claims 1-15, drawn to products and methods of using the compound of formula (I) where X is NH; Y is -NH-CO; Ar1

and Ar₂ are phenyl; A is -C(=NH)NH₂, G is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and R₃ is substituted phenyl. An example of an embodiment of such invention group is the compound of Example 45, which is 2-(3-Carbamimidoyl-phenylamino)-N-[4-(morpholin-4-carbonyl)-phenyl]-2-[2-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-acetamide). The provision of such example herein is intended only to aid the Office and is not to be understood as any further election over Group I, for example a species election.

Applicants hereby reserve the right to pursue non-elected invention groups (for example, Group II (claims 1-15), Group III (claims 1-15), Group IV (claims 1-15), Group V (Claims 16-18), or any other invention group) in this application where rejoinder is appropriate or in a subsequently filed application claiming the benefit of the present application. It is Applicants' understanding that the substituted phenyl of R₃, as described by the Office in invention Group I, is not directed to a particular substitution position or moiety.

Applicants herein present new claims 19-20. Claim 19 corresponds to the independent claim of issued European Patent EP1470143 (in German), which is the priority document for PCT/EP2003/001011 (published as WO2003/064440), from which the present application was filed.

In traversing the restriction requirement, Applicants respectfully assert that examination and issuance of corresponding claims in EP1470143 provides *prima facie* evidence that at least claims 19-20 of the present application are not drawn to more than one inventive concept and that the special technical features of claims 19-20 provide a technical relationship sufficient to establish unity of invention. Applicants respectfully request the Office to classify at least claims 19-20 in a single invention Group and provide substantive examination thereof.

CONCLUSION

Applicants believe that the claims as presented represent allowable subject matter. If the Office desires, Applicants welcome a telephone interview to expedite prosecution. As always, the Office is free to call the undersigned at the number below. Applicants believe there is a \$225.00 fee for a two month extension due at this time. The Commissioner is hereby authorized to deduct any deficiency or credit any overpayment with respect to this response to Deposit Account No. 19-3140.

Respectfully submitted,

SONNENSCHN NATH & ROSENTHAL LLP

By: /David R. Metzger/
David R. Metzger
Reg. No. 32,919
Telephone No. 312.876.2578

ATTORNEYS FOR APPLICANT